Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells (Q82206056)
Jump to navigation
Jump to search
scientific article published on 02 October 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells |
scientific article published on 02 October 2008 |
Statements
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells (English)
Sandrine d'Argouges
Sandra Wissing
Christian Brandl
Nadja Prang
Ralf Lutterbuese
Alex Kozhich
Joann Suzich
Mathias Locher
Peter Kiener
Peter Kufer
Robert Hofmeister
Ralf C Bargou
2 October 2008